How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,227 results for

Desmopressin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Kidney Pre-biopsy medication: Desmopressin acetate

Kidney Pre-biopsy medication: Desmopressin acetate ____________________________________________________________________________________________________________ Renal Biopsy - Desmopressin Acetate July 2018 Page 1 of 11 3. PRE – BIOPSY MEDICATION - DESMOPRESSIN ACETATE Date written: March 2018 Author: Emily See, Paul Champion de Crespigny, Pamela Lopez-Vargas, Talia Gutman, Karine Manera, Solomon Menahem, John Saunders, David Voss, Jeffrey Wong and Rob MacGinley. GUIDELINES No recommendations (...) or suggestions can be made due to lack of evidence. UNGRADED SUGGESTIONS FOR CLINICAL CARE ? There is a lack of evidence to support the benefit or harm of desmopressin acetate 0.3µg/kg administered intravenously over 30 minutes prior to renal biopsy. Units should continue their existing practice until a higher level of evidence is available. However, we suggest this is considered only for patients with Stage 3b chronic kidney disease and onwards. ? Careful attention to fluid balance should be paid

2020 KHA-CARI Guidelines

2. Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. Full Text available with Trip Pro

Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. Congenital bleeding disorders can cause obstetric haemorrhage during pregnancy, labour and following delivery. Desmopressin acetate (DDAVP) is found to be an effective drug which can reduce the risk of haemorrhage and can also stop bleeding in certain congenital bleeding disorders. Its use in pregnancy has been controversial. Hence beneficial and adverse effects

2019 Cochrane

3. Desmopressin acetate (Noqdirna) - idiopathic nocturnal polyuria

Desmopressin acetate (Noqdirna) - idiopathic nocturnal polyuria Final Appraisal Recommendation Advice No: 1617 – September 2017 Desmopressin acetate (Noqdirna ® ) 25 microgram and 50 microgram oral lyophilisate Submission by Ferring Pharmaceuticals Additional note(s): • Cost-effectiveness evidence was only provided for a subpopulation of patients aged over 65. In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference (...) recommendation being quoted in full and cited as: All Wales Medicines Strategy Group Final Appraisal Recommendation – 1617: Desmopressin acetate (Noqdirna ® ) 25 microgram and 50 microgram oral lyophilisate September 2017 Recommendation of AWMSG Desmopressin acetate (Noqdirna ® ) for the treatment of nocturia due to idiopathic nocturnal polyuria in adults is recommended for restricted use within NHS Wales. Desmopressin acetate (Noqdirna ® ) should be restricted for use in the following subpopulation within

2017 All Wales Medicines Strategy Group

4. Nocdurna (desmopressin) - for symptomatic treatment of nocturia

Nocdurna (desmopressin) - for symptomatic treatment of nocturia Nocdurna® (desmopressin) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Nocdurna® (desmopressin) Conclusion Nocdurna was marketed in Denmark in August 2016 for symptomatic treatment of nocturia caused by idiopathic nocturnal polyuria in adults. Nocdurna differs from existing desmopressin products by its lower strengths of respectively 25 µg and 50 µg per tablet, enabling a lower dose (...) compared to other desmopressin tablets whose lowest dose is 60 µg. Nocdurna is especially suited for elderly patients as treatment with desmopressin in elderly patients is associated with a dose-dependent increased risk of hyponatraemia, which is the reason why the existing products on the market are not recommended in the elderly. Unlike the other desmopressin products, Nocdurna is not authorised for treatment of nocturnal enuresis and diabetes insipidus. In comparable placebo studies, the efficacy

2017 Danish Pharmacotherapy Reviews

6. Desmopressin/indomethacin combination efficacy and safety in renal colic pain management: A randomized placebo controlled trial (Abstract)

Desmopressin/indomethacin combination efficacy and safety in renal colic pain management: A randomized placebo controlled trial Renal colic is a prevalent cause of abdominal pain in the emergency department. Although non-steroidal anti-inflammatory drugs and opioids are used for the treatment of renal colic, some adverse effects have been reported. Therefore, desmopressin -a synthetic analogue of vasopressin- has been proposed as another treatment choice. In the present study, indomethacin (...) in combination with nasal desmopressin was compared with indomethacin alone in the management of renal colic.Included in the study were 124 patients with initial diagnosis of renal colic and randomized to receive indomethacin suppository (100 mg) with either desmopressin intranasal spray (4 puffs, total dose of 40 micrograms) and or placebo intranasal spray.All the included patients were finally diagnosed with renal colic. There was no difference between the two groups in pain at the baseline (p = 0.4

2019 EvidenceUpdates

7. Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. (Abstract)

Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. Congenital bleeding disorders can cause obstetric haemorrhage during pregnancy, labour and following delivery. Desmopressin acetate is found to be an effective drug which can reduce the risk of haemorrhage and can also stop bleeding in certain congenital bleeding disorders. Its use in pregnancy has been controversial. Hence beneficial and adverse effects (...) of desmopressin acetate in these groups of pregnant women should be evaluated.This is an update of a Cochrane review first published in 2013.To determine the efficacy of desmopressin acetate in preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders.We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Coaguopathies Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant

2015 Cochrane

8. A decreased and less sustained desmopressin response in hemophilia A carriers contributes to bleeding Full Text available with Trip Pro

A decreased and less sustained desmopressin response in hemophilia A carriers contributes to bleeding The cause of hemophilia A carrier bleeding is not well established. Desmopressin (DDAVP), used clinically to treat or prevent bleeding, can also be used as a medical stress surrogate. This study's objective was to compare the response to DDAVP in hemophilia A carriers with that in normal control patients. Bleeding was assessed by the International Society on Thrombosis and Hemostasis Bleeding

2018 Blood advances

9. Nocturia and nocturnal polyuria in men with lower urinary tract symptoms: oral desmopressin

Nocturia and nocturnal polyuria in men with lower urinary tract symptoms: oral desmopressin Nocturia and nocturnal polyuria in men with lower urinary tract symptoms: oral desmopressin | Advice | NICE Nocturia and nocturnal polyuria in men with lower urinary tract symptoms: oral desmopressin Evidence summary [ESUOM10] Published date: April 2013 Advice This evidence summary has been withdrawn because a product containing oral desmopressin with a marketing authorisation for treating nocturia

2013 National Institute for Health and Clinical Excellence - Advice

10. Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. (Abstract)

Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. Congenital bleeding disorders can cause obstetric haemorrhage during pregnancy, labour and following delivery. Desmopressin acetate is found to be an effective drug which can reduce the risk of haemorrhage and can also stop bleeding in certain congenital bleeding disorders. Its use in pregnancy has been controversial. Hence beneficial and adverse effects (...) of desmopressin acetate in these groups of pregnant women should be evaluated.To determine the efficacy of desmopressin acetate in preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders.We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Coaguopathies Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant and abstract books of conferences proceedings. We also searched for any

2013 Cochrane

11. Effect of local desmopressin administration on intraoperative blood loss and quality of the surgical field during functional endoscopic sinus surgery in patients with chronic rhinosinusitis: a triple-blinded clinical trial. (Abstract)

Effect of local desmopressin administration on intraoperative blood loss and quality of the surgical field during functional endoscopic sinus surgery in patients with chronic rhinosinusitis: a triple-blinded clinical trial. Bleeding during functional endoscopic sinus surgery always been a challenge for the quality of surgical field for surgeons. This study aimed to evaluate the effect of local nasal desmopressin premedication on blood loss and the quality of surgical field in functional (...) endoscopic sinus surgery.This study was conducted on 90 patients with chronic rhinosinusitis who were candidate for endoscopic sinus surgery. They were randomly assigned to two study groups. One group received a single puff of local desmopressin (10 μg) in each side of nasal cavity 30 min before the surgery and the other received normal saline instead. Blood loss and the quality surgical field were determined in 15, 30, 60 and 90 min during the surgery (scoring by BOEZAART grading system). All data were

2019 European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery Controlled trial quality: uncertain

12. Retrospective Assessment of Desmopressin Effectiveness and Safety in Patients With Antiplatelet-Associated Intracranial Hemorrhage. (Abstract)

Retrospective Assessment of Desmopressin Effectiveness and Safety in Patients With Antiplatelet-Associated Intracranial Hemorrhage. Current international guidelines offer a conditional recommendation to consider a single dose of IV desmopressin (DDAVP) for antiplatelet-associated intracranial hemorrhage based on low-quality evidence. We provide the first comparative assessment analyzing DDAVP effectiveness and safety in antiplatelet-associated intracranial hemorrhage.Retrospective chart

2019 Critical Care Medicine

13. Efficacy and safety of 25 and 50 μg desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: Results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group devel Full Text available with Trip Pro

Efficacy and safety of 25 and 50 μg desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: Results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group devel This study assessed the efficacy and safety of desmopressin orally disintegrating tablets (ODTs) in Japanese males (50 and 25 μg) and females (25 μg) with nocturia due to nocturnal polyuria (NP). Two Phase 3 randomized double-blind placebo (...) -controlled studies of 342 males and 190 females with nocturia due to NP were conducted. The primary endpoint was change from baseline in mean number of nocturnal voids. In addition, time to first awakening to void, nocturnal urine volume, NP index (NPI), and quality of life were assessed during a 12-week treatment period. In males, 50 and 25 μg desmopressin ODTs significantly reduced the number of nocturnal voids by -1.21 (P < .0001) and - 0.96 (P = .0143), respectively, and significantly prolonged

2019 Lower urinary tract symptoms Controlled trial quality: uncertain

14. The Hemostatic Effect of Desmopressin on Bleeding as a Nasal Spray in Open Septorhinoplasty. (Abstract)

The Hemostatic Effect of Desmopressin on Bleeding as a Nasal Spray in Open Septorhinoplasty. Rhinoplasty is associated with intraoperative bleeding which affects the quality of the operation and may increase the time of surgery. The aim of this study was to assess the role of nasal spray of desmopressin on reduction in intraoperative bleeding during elective open rhinoplasty.Conducting an interventional study in our hospital, all patient data including demographic information, medical history (...) and laboratory tests before surgery were collected. Patients who were randomly divided into two study groups, received nasal desmopressin spray or placebo spray, 60 min before starting open septorhinoplasty. The measured variables included: bleeding volume, the operative field quality in regard to bleeding (Boezaart score), the surgeons' satisfaction in regard to bleeding during surgery (Likert scale), postoperative bruising, postoperative bleeding and menstruation.Thirty cases were studied; 13 (46.3

2019 Aesthetic plastic surgery Controlled trial quality: uncertain

15. Low-dose Desmopressin Orally Disintegrating Tablet: Suggested Clinically Meaningful Benefit in Patients with Nocturia Due to Nocturnal Polyuria. (Abstract)

Low-dose Desmopressin Orally Disintegrating Tablet: Suggested Clinically Meaningful Benefit in Patients with Nocturia Due to Nocturnal Polyuria. Clinical benefit has not been evaluated much in patients with nocturia.To assess the clinical benefit of desmopressin orally disintegrating tablet (ODT) in women (25μg) and men (50μg) with nocturia due to nocturnal polyuria (NP).Patients with NP from two randomised, placebo-controlled trials in men (CS41) and women (CS40) with two or more nocturnal (...) ) were similar. A greater reduction in the mean number of nocturnal voids was seen with desmopressin ODT in men (treatment difference [TD]: -0.37 voids) compared with women (TD: -0.29 voids). For 33% and 50% responder status, TD with ODT versus placebo were 21% and 12%, respectively, in men, and 12% and 17%, respectively, in women. For the number of nights with at most one void, TDs were 11% and 13% (p<0.009 for both) for men and women, respectively. For complete response, TD was significant in men

2018 European urology focus Controlled trial quality: uncertain

16. Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study. Full Text available with Trip Pro

Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study. Haemophilia A is an inherited bleeding disorder characterised by factor VIII (FVIII) deficiency. In patients with non-severe haemophilia A, surgery and bleeding are the main indications for treatment with FVIII concentrate. A recent study reported that standard dosing frequently results in FVIII levels (FVIII:C) below (...) or above FVIII target ranges, leading to respectively a bleeding risk or excessive costs. In addition, FVIII concentrate treatment carries a risk of development of neutralising antibodies. An alternative is desmopressin, which releases endogenous FVIII and von Willebrand factor. In most patients with non-severe haemophilia A, desmopressin alone is not enough to achieve FVIII target levels during surgery or bleeding. We hypothesise that combined pharmacokinetic (PK)-guided administration of desmopressin

2019 BMJ open

17. Pharmacokinetics and safety profile of desmopressin oral tablet formulations in healthy Chinese subjects under fasting and fed conditions. (Abstract)

Pharmacokinetics and safety profile of desmopressin oral tablet formulations in healthy Chinese subjects under fasting and fed conditions. Desmopressin acetate (DDAVP®) is a synthetic analogue of the pituitary hormone vasopressin. Until now, few studies of desmopressin have focused on the pharmacokinetics (PK) or food effects in Asian populations. This study aimed to assess the effect of food intake on the PK of desmopressin and bioequivalence of two tablet formulations in Chinese subjects.A (...) single-center, single-dose, randomized, open-label, two-period crossover study was conducted in 104 healthy Chinese volunteers under fasted or fed conditions (52 volunteers for each condition). Blood samples were collected up to 14 hours after administration of oral desmopressin tablets (0.6 mg; 0.2 mg × 3) in each period. Plasma desmopressin concentrations were analyzed by validated liquid chromatography-tandem mass spectrometry (LC-MS/MS). PK and bioavailability parameters were calculated. Adverse

2018 International journal of clinical pharmacology and therapeutics

18. Do independent geriatric outpatients with nocturnal polyuria profit from desmopressin? (Abstract)

Do independent geriatric outpatients with nocturnal polyuria profit from desmopressin? To compare the efficacy of desmopressin and placebo in independent geriatric outpatients with nocturnal polyuria (NP).A prospective, randomized, single-center, national, double blind, placebo-controlled, fixed-dose, parallel group comparative trial was carried out. The study included 110 geriatric outpatients, 55 patients per treatment group using desmopressin acetate nasal spray (strength: 0.1 mg/ml) once (...) ) was 50% versus 41.40% in the verum versus placebo group, respectively but the differences were not significant. The U‑test showed superiority of AVP-positive NP patients to a positive reaction on desmopressin. Sleeping time hours increased in both groups without significant differences.In this 10-day clinical trial desmopressin was not proven to be therapeutically superior to placebo with respect to micturition frequency or sleeping hours. Independent geriatric outpatients with decreased ADH levels

2018 Zeitschrift Fur Gerontologie Und Geriatrie Controlled trial quality: uncertain

19. Low-dose Desmopressin and Tolterodine Combination Therapy for Treating Nocturia in Women with Overactive Bladder: A Double-blind, Randomized, Controlled Study. (Abstract)

Low-dose Desmopressin and Tolterodine Combination Therapy for Treating Nocturia in Women with Overactive Bladder: A Double-blind, Randomized, Controlled Study. Evaluation of safety and efficacy of desmopressin/tolterodine combination therapy in women.This double-blind, randomized, proof-of-concept study enrolled 106 patients (≥18 years), with overactive bladder (OAB) and nocturia, with ≥2 nocturnal voids, receiving a 3-month once-daily combination (desmopressin 25 µg, orally-disintegrating (...) improvement in NI Diary© scores. Safety profile was comparable between treatments. A single transient event of asymptomatic clinically significant hyponatremia in combination group resolved subsequently.Low-dose desmopressin could be safely combined with tolterodine for treating nocturia in women with OAB, with a significant benefit in women with NP. Further, prospective validation studies of combination therapy are warranted in mixed NP/OAB population, based on this favorable proof-of-concept finding.©

2018 Lower urinary tract symptoms Controlled trial quality: predicted high

20. Emergency coronary bypass surgery in patients under the influence of dualantiplatelet therapy: effects of tranexamic acid and desmopressin acetate Full Text available with Trip Pro

Emergency coronary bypass surgery in patients under the influence of dualantiplatelet therapy: effects of tranexamic acid and desmopressin acetate Background/aim: Bleeding in patients undergoing coronary artery bypass grafting (CABG) while using dual antiplatelet therapy (DAPT) is a cause of significant morbidity and mortality. The aim of this study is to examine the perioperative hemostatic effects of tranexamic acid (TnX-A) and desmopressin acetate (Des) in these patients. Materials

2018 Turkish Journal of Medical Sciences Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>